SAN DIEGO, Aug. 5, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9,2024 and March 25, 2026 (the "Class Period"). ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What Are the Allegations Against ADMA?
Shareholders allege that ADMA Biologics, Inc. (ADMA) misled investors regarding its business operations. According to the complaint, during the class period, defendants made false and/or misleading statements and/or failed to disclose that:
- ADMA Biologics engaged in an undisclosed related party transaction;
- ADMA Biologics used channel stuffing to create an appearance of revenue;
- ADMA Biologics lacked adequate internal controls; and
- as a result, defendants' statements about ADMA Biologics' business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Plaintiff alleges that on March 24, 2026, Culper Research issued a report entitled "ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported." Among other things, the report alleged that ADMA's reported growth was driven by channel stuffing and an undisclosed related party distributor, that ADMA used channel stuffing to create an appearance of revenue growth, and that ADMA failed to disclose a material distribution relationship with Genesis BioPharma Services, an entity that allegedly operated from ADMA's corporate headquarters. On this news, the price of ADMA stock fell $2.26 per share, or 16.6%, to close at $11.33 per share on March 24, 2026, and fell an additional $1.70 per share, or 15.0%, on March 25, 2026.
Who Is Eligible to Participate in the Class Action?
Stockholders who purchased shares of ADMA during the Class Period have an opportunity to serve as lead plaintiff for the class must. Interested shareholders must file their papers with the court by August 10, 2026.
The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP
A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $1 billion in value to shareholders, secured some of the largest recoveries in shareholder derivative litigation history, and achieved governance reforms at over 400 Fortune 1000 companies.
"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP.
To be notified if a class action against ADMA Biologics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
View original content to download multimedia:https://www.prnewswire.com/news-releases/robbins-llp-reminds-adma-investors-of-the-august-10-2026-lead-plaintiff-deadline-contact-the-firm-for-information-about-recovering-your-losses-302843084.html
SOURCE Robbins LLP
